-
Uncategorized4 weeks agoScientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases
Researchers from the International Institute of Molecular and Cell Biology in Warsaw (IIMCB) say they have created the first systematic catalog of the substrate receptors of...
-
Uncategorized4 weeks agoRegeneron to challenge Ipsen as FDA clears bone disease drug
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
-
Uncategorized4 weeks agoCancer vaccine win restores Wall Street’s faith in Moderna
Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and...
-
Uncategorized4 weeks ago
Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe’s early-stage IPO standout defies biotech’s derisking trend
-
Uncategorized4 weeks agoSTAT+: How a Trump loyalist got the FDA nomination
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your...
-
Uncategorized4 weeks agoSTAT+: FDA approves Ultragenyx gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk more about...
-
Uncategorized4 weeks agoDDII Digital Forum: Resilience, smarter labs, therapeutics, and capital flows
The Drug Discovery Innovators & Investors (DDII) Digital Forum, taking place on 30 September 2026, will bring together experts from across the drug discovery ecosystem to...
-
Uncategorized4 weeks agoSTAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where...
-
Uncategorized4 weeks ago
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
-
Uncategorized4 weeks agoBuilt Without Bacteria: Bringing Cell-Free Synthesis to the Bench
Register Now Matthew D. Youngblut, PhD Co-founder and Chief Scientific OfficerFlock Bio View Bio Panelist Matthew D. Youngblut, PhD Matthew Youngblut, PhD, is the co-founder and...
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
